Back | Next |
home / stock / abbv / abbv message board
Subject | By | Source | When |
---|---|---|---|
$ABBV 1Q22 CC transcript: | DewDiligence | investorshub | 05/01/2022 5:58:44 PM |
Didn't expect that. Bailed and wiped out most | retired early | investorshub | 04/29/2022 2:46:17 PM |
$ABBV 1Q22 results: | DewDiligence | investorshub | 04/29/2022 12:29:28 PM |
Or perhaps we are done correcting? :) | retired early | investorshub | 04/27/2022 7:29:46 PM |
Thanks DewDilligence, you are most likely right about | Just the facts maam | investorshub | 04/25/2022 11:18:19 AM |
Androgel is now available as a generic, so | DewDiligence | investorshub | 04/24/2022 3:56:36 PM |
Question for the board, is AbbVie interested in | Just the facts maam | investorshub | 04/24/2022 11:05:00 AM |
whytestocks: $ABBV News Article - LAWSUITS FILED AGAINST GATO, ABBV and AUPH - Jakubowitz Law Pursue | whytestocks | investorshangout | 04/21/2022 6:50:53 PM |
Up too fast perhaps. Maybe a new 120 base? | retired early | investorshub | 04/17/2022 3:58:23 PM |
$ABBV Chart | conix | investorshub | 04/17/2022 12:46:09 PM |
whytestocks: $ABBV News Article - Best Biotech Stocks To Buy Now? 5 To Know | whytestocks | investorshangout | 04/14/2022 5:55:49 PM |
whytestocks: $ABBV News Article - AbbVie to Host First-Quarter 2022 Earnings Conference Call | whytestocks | investorshangout | 04/14/2022 4:45:50 PM |
$ABBVs #2 executive, Mike Severino, is leaving to | DewDiligence | investorshub | 04/13/2022 4:27:08 PM |
Wow a $13 mil buy @ end | retired early | investorshub | 04/03/2022 2:42:52 PM |
FDA approves Rinvoq for second-line ulcerative colitis: | DewDiligence | investorshub | 03/17/2022 12:40:47 AM |
Recent investor. Looks like a safer long term | retired early | investorshub | 03/15/2022 3:19:48 PM |
$ABBV reports positive Qulipta phase-3 in prevention of | DewDiligence | investorshub | 03/10/2022 2:34:31 PM |
Alvotech settles Humira-US-patent litigation with $ABBV: | DewDiligence | investorshub | 03/09/2022 12:33:11 AM |
Skyrizi PDUFA date for Crohns disease extended three | DewDiligence | investorshub | 03/01/2022 12:32:11 AM |
Rinvoq succeeds in second Phase-3 in Crohns: | DewDiligence | investorshub | 02/24/2022 4:48:04 PM |
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 08:25:00 ET Stocks that are trading at low- and discounted-earnings multiples can sometimes be value traps. But other times, it's just due to short-term and temporary factors that the stocks aren't doing terribly well. In these situations, there are opportunities for investors to...
2024-07-14 04:27:00 ET The broader stock market benchmarks keep reaching new heights, but the S&P 500 index's ongoing bull run has been driven heavily by its largest components. That means there are still plenty of reliable dividend-paying stocks that look like bargains. Shares ...
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis PR Newswire Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endp...